Pharma Mar, S.a.

Parma Mar, S.a.

Juan Manuel Zapata Hernández

Andrés Francesch Solloso

María Garranzo García-Ibarrola

Francisco Sánchez Madrid

Alicia García Arroyo

Maria Del Carmen Cuevas Marchante

Juan Manuel Domínguez Correa

Carmen Cuevas Marchante

Maria Garranzo Garcia-Ibarrola

Cármen Cuevas Marchante

María José Munoz Alonso

Juan Manuel Dominguez Correa

Maria Jose Munoz Alonso

Maria Angeles Ursa Pecharroman

Maria Ángeles Ursa Pecharromán

Alicia Garcia Arroyo

Maria ÁNgeles Ursa PECHARROMÁN

Francisco Sanchez Madrid

Drug conjugates of formula [D-(X)-(AA)-(L)-]-Ab wherein:

Antibody drug conjugates

Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R, Rand Ris H, OR, OCOR, OCO&#x2014;OR, alkyl, alkenyl, alkynyl, etc.; R' is, COR, COOR, CONRR, etc; each of Rto Rand Ris alkyl, alkenyl or alkynyl; Ris H, COR, COOR, alkyl, alkenyl or alkynyl, or Rand R+N+C atoms to which they are attached may form a heterocyclic group; each of Rand Ris H, COR, COOR, alkyl, alkenyl or alkynyl; each Rand Ris H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group [D-(X)-(AA)-(L)-] to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer. 

Growing community of inventors

Madrid, Spain

Juan Manuel Zapata Hernández